Adult-onset Still's disease
Conditions
Interventions
Group 1:Baricitinib therapy
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients who fulfill Yamaguchi's diagnostic criteria after evaluation; 2. Patients with a clear diagnosis of AOSD after the possibility of infection, malignancy, and other rheumatic immune diseases have been excluded; 3. Patients with refractory AOSD for whom conventional treatment is ineffective or ineffective, further leading to relapse; 4. Aged 18-65 years; 5. Voluntarily subjected to the trial and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those who have been diagnosed with other rheumatic immune diseases such as systemic lupus erythematosus, dry syndrome, myositis, or dermatomyositis; 2. Those with a combination of serious primary diseases of the cardiovascular, hepatic, renal, and hematopoietic systems, psychiatric patients; 3. The presence of active infectious diseases or chronic infectious diseases; 4. Women who are pregnant, breastfeeding, or have a pregnancy planned during treatment; 5. Those with a history of drug or substance abuse or alcoholism; 6. The investigator deemed cases inappropriate for inclusion in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Systemic score;Pred dosage; | — |
Countries
China
Contacts
Public ContactXin Li
Tianjin Medical University General Hospital
Outcome results
None listed